In the first half of this fiscal year we have continued our proven trajectory with double-digit growth rates and increased profitability. Our long-term delivery contracts with leading pharma companies, extending partially until 2030 and beyond, provide high security and financial visibility. This sets a solid foundation for our future success,” said Salvatore De Furia , Ceo Pharmintechs Group. The company has made rapid progress in implementing the production expansion plan for its high-value product lines, ensuring its ability to meet growing market demand. Amongst others,Pharmintechs Group has added a state-of-the-art production facility for prefillable syringes in South England and is significantly expanding capacity for its ready-to-use vials in the United States. In addition, the company has also started construction of a new manufacturing hub for prefillable glass Syringes in United Kingdom
News Update
